Product Description
Mechanisms of Action: APM1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chroma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Myelodysplastic Syndrome|Acute Myeloid Leukemia
Phase 2: Preleukemia|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Multiple Myeloma|Leukemia, Plasma Cell|Pancreatic Cancer|Adenocarcinoma|Anemia, Refractory, with Excess of Blasts
Phase 1: Oncology Solid Tumor Unspecified|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2006-7041-83/hah | N/A |
Not yet recruiting |
Surgical Wound Infection |
2020-05-04 |
|
NCI-2018-01817 | P1 |
Terminated |
Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome |
2019-07-04 |
|
LI-1 | P3 |
Unknown status |
Acute Myeloid Leukemia|Myelodysplastic Syndrome |
2019-05-04 |
|
MUK three | P2 |
Completed |
Multiple Myeloma |
2017-10-30 |